"I chose to have my acne scars treated because I felt when people looked at me they didn't see the real me, they just saw my scars," stated Katelyn Baker, a patient of the Gold Skin Care Center in Nashville, Tennessee. "I've had two pain-free treatments with Sublative and my skin is smoother, more filled out, and has a natural glow. I am now more confident and feel that people are focusing on me now instead of looking at my scars."
Louis Scafuri, Chief Executive Officer of Syneron, said, "We have received very positive physician and patient feedback on the Sublative technology since its introduction in 2009. This fractional bi-polar radio frequency technology delivers excellent results with little-to-no downtime and is a safe and more effective treatment alternative for all skin tones. The addition of an acne scar treatment further expands its clinical utility and will allow our customers to address a large and underserved segment of the aesthetic market. We look forward to supporting the expanded treatment with the launch of our "Skinhibitions" focused consumer marketing campaign, which will help increase awareness of the excellent results that can be achieved in treating acne scars with the Sublative technology."Syneron will introduce the new acne scar treatment for its Sublative compatible platforms and its new "Skinhibitions" consumer campaign at the American Society of Laser Medicine & Surgery annual conference in Boston, Massachusetts from April 3-7, 2013 and at the Anti-Aging Medicine World Congress & Medispa in Monte-Carlo, Monaco from April 4-6, 2013. About Syneron Medical Ltd. Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts